MIYAMOTO SHINTAROU

ミヤモトシンタロウ | MIYAMOTO SHINTAROU

Affiliation and department：

Research keywords (4)： Patient Safety , Bronchial Asthma , Allergology , Respiratory Medicine

Research theme for competitive and other funds (3)：

2019 - 2023 粉末siRNA製剤を用いたCCL15を標的とする気管支喘息の新規経気道治療の開発
2019 - 2022 粉末siRNA製剤を用いたCCL15を標的とする気管支喘息の新規経気道治療の開発
2020 - 2021 サノフィ株式会社研究・教育支援(奨学寄附)

Papers (23)：

Yamaguchi, Kakuhiro, Iwamoto, Hiroshi, Mazur, Witold, Miura, Shinichiro, Sakamoto, Shinjiro, Horimasu, Yasushi, Masuda, Takeshi, Miyamoto, Shintaro, Nakashima, Taku, Ohshimo, Shinichiro, et al. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis. RESPIRATORY RESEARCH. 2020. 21. 1. 145-145
Masuda, Takeshi, Fujitaka, Kazunori, Ishikawa, Nobuhisa, Nakano, Kikuo, Yamasaki, Masahiro, Kitaguchi, Souichi, Masuda, Ken, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Horimasu, Yasushi, et al. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer. JOURNAL OF THORACIC DISEASE. 2020. 12. 3. 1079-1084
Ninomiya, Kiichiro, Hata, Tae, Yoshioka, Hiroshige, Ohashi, Kadoaki, Bessho, Akihiro, Hosokawa, Shinobu, Ishikawa, Nobuhisa, Yamasaki, Masahiro, Shibayama, Takuo, Aoe, Keisuke, et al. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). CHEST. 2019. 156. 2. 357-366
Shioya S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, et al. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia. Respiratory medicine. 2019. 152. 44-50
Masashi Namba, Noboru Hattori, Hironobu Hamada, Kakuhiro Yamaguchi, Yohei Okamoto, Taku Nakashima, Takeshi Masuda, Shinjiro Sakamoto, Yasushi Horimasu, Shintaro Miyamoto, et al. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1. Cancer Letters. 2019. 442. 31-39

ｍore...

Lectures and oral presentations (154)：

デュピルマブが有効であったオマリズマブ抵抗性の重症喘息合併アナフィラキシーの1例
(第4回日本アレルギー学会中国四国地方会 2022)
診断に苦慮したクロピドグレルによる薬剤性好酸球性胸水の一例
(第30回日本呼吸器内視鏡学会中国四国支部会 2021)
PAI-1はEGFR遺伝子変異陽性肺腺癌の EGFRチロシンキナーゼ阻害薬に対する耐性獲得に関与する
(第62回肺癌学会学術集会 2021)
免疫チェックポイント阻害薬による肺障害の発症を予測する血液マーカーとしてのHMGB1の有用性の検討
(第62回日本肺癌学会学術集会 2021)
自己抗体陽性の間質性肺炎合併肺癌患者における化学療法による急性増悪の特徴の検討
(第62回日本肺癌学会学術集会 2021)

ｍore...

Work history (6)：

2018/01/01 - Hiroshima University Hospital Lecturer
2015/04/01 - 2017/12/31 Hiroshima University Hospital Assistant Professor
2012/04/01 - 2015/03/31 Kochi University Assistant Professor
2011/04/01 - 2012/03/31 Hiroshima University Hospital Clinical Fellow
2010/01/01 - 2011/03/31 Hiroshima University Hospital Clinical Staff

Show all

Awards (1)：

2011/03/13 - 第2回 Innovative Asthma Association(IAA)研究会 IAA Award 2010 最優秀賞喘息モデルマウスにおける Plasminogen Activator Inhibitor-1(PAI-1)に対するsiRNAの経気道投与の効果

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page